EUVIMEDEUVIMED entdecken
Crossref

Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma

Zikun Yu, Qin Wang, Zimeng Wang, Sihan Liu, Tianliang Xia, Chongyang Duan, Youping Liu, Xi Ding, Siyuan Chen, Tao Yu, Rui You, Mingyuan Chen und 1 weitere

Head & Neck · 2025-01 · 47 (1) · 269-281

DOI: 10.1002/hed.27917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 12.08.2024. Verfasst von Zikun Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Cli…. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Gastrointestinal Microbiome, Nasopharyngeal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key-Area Research and Development of Guangdong Province, Startup Funds for Staff Trained Overseas of Sun Yat-sen University Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Effective biomarkers for assessing anti‐PD‐1/PD‐L1 therapy efficacy in patients with nasopharyngeal carcinoma (NPC) are still lacking. The human gut microbiota has been shown to influence clinical response to anti‐PD‐1/PD‐L1 therapy in many cancers. However, the relationship between the gut microbiota and the efficacy of immunotherapy in patients with nasopharyngeal carcinoma has not been determined.

Methods

We conducted a prospective study in which fecal and blood samples from patients with NPC were subjected to 16S rDNA sequencing and survival analysis. To investigate potential differences in the gut microbiome between these groups and to identify potential biomarkers indicative of immunotherapy efficacy, patients were categorized into two groups according to their clinical response to immunotherapy, the responder group (R group) and the non‐responder group (NR group). Progression‐free survival (PFS) between these subgroups was analyzed using Kaplan–Meier survival analysis with the log‐rank test. Additionally, we performed univariate and multivariate analyses to evaluate prognostic factors. Finally, we carried out non‐targeted metabolomics to examine the metabolic effects associated with the identified microbiome.

Results

Our 16S rDNA sequencing results showed that the abundance of Lachnoclostridium was higher in the NR group than in the R group ( p = 0.003), and alpha diversity analysis showed that the abundance of microbiota in the NR group was higher than that in the R group ( p = 0.050). Patients with a lower abundance of Lachnoclostridium had better PFS ( p = 0.048). Univariate ( p = 0.017) and multivariate analysis ( p = 0.040) showed that Lachnoclostridium was a predictor of PFS. Non‐targeted metabolomics analysis revealed that Lachnoclostridium affects the efficacy of immunotherapy through the usnic acid.

Conclusions

High abundance of Lachnoclostridium predicts poor prognosis in patients with NPC receiving immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaGastrointestinal MicrobiomeNasopharyngeal NeoplasmsImmunotherapyHumansMaleFemaleMiddle AgedProspective StudiesAdultAgedEubacterialesProgression-Free SurvivalFecesTreatment OutcomeKaplan-Meier Estimate

Stichwörter der Autor:innen

Lachnoclostridiumgut microbiomeimmunotherapynasopharyngeal carcinoma

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center…
  • Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.
  • Nasopharyngeal Cancer Prevention Center, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.

Förderung

  • National Natural Science Foundation of China
  • Key-Area Research and Development of Guangdong Province
  • Startup Funds for Staff Trained Overseas of Sun Yat-sen University Cancer Center
  • Program of Sun Yat-Sen University for Clinical Research 5010 Program

Zitieren

APA

Yu, Z., Wang, Q., Wang, Z., Liu, S., Xia, T., Duan, C., Liu, Y., Ding, X., Chen, S., Yu, T., You, R., Chen, M., & Huang, P. (2025). Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma. Head & Neck, 47(1), 269-281. https://doi.org/10.1002/hed.27917

Vancouver

Yu Z, Wang Q, Wang Z, Liu S, Xia T, Duan C, et al. Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma. Head & Neck. 2025;47(1):269-281. doi:10.1002/hed.27917

BibTeX
@article{Yu2025,
  author = {Yu, Zikun and Wang, Qin and Wang, Zimeng and Liu, Sihan and Xia, Tianliang and Duan, Chongyang and Liu, Youping and Ding, Xi and Chen, Siyuan and Yu, Tao and You, Rui and Chen, Mingyuan and Huang, Peiyu},
  title = {Lachnoclostridium intestinal flora is associated with immunotherapy efficacy in nasopharyngeal carcinoma},
  journal = {Head & Neck},
  year = {2025},
  volume = {47},
  number = {1},
  pages = {269--281},
  doi = {10.1002/hed.27917}
}
Kostenlos starten →